Pfizer’s experimental drug

Pfizer reported positive trial results from its latest trial of an experimental breast cancer drug, which doubled the lifetime of patients on the medication, but survival rates were not significantly lower. Pfizer shares ended three percent lower, the biggest decliner on the Dow today.

This entry was posted in Biotech & Pharmaceuticals, NBR Show Clips. Bookmark the permalink.

Leave a Reply